{"id":503559,"date":"2024-07-19T11:19:23","date_gmt":"2024-07-19T03:19:23","guid":{"rendered":"https:\/\/law.asia\/?p=503559"},"modified":"2024-07-19T11:19:23","modified_gmt":"2024-07-19T03:19:23","slug":"simpson-nishimura-japan-pharma-buyout","status":"publish","type":"post","link":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/","title":{"rendered":"Simpson \ubc0f Nishimura, 3\uc870\uc6d0\ub300 \uaddc\ubaa8 \uc77c\ubcf8 \uc81c\uc57d\uc0ac \uc778\uc218\uc5d0 \uc790\ubb38 \uc81c\uacf5"},"content":{"rendered":"<p>Simpson Thacher &amp; Bartlett\uacfc Nishimura &amp; Asahi\uac00 \uc77c\ubcf8\uc758 \uc8fc\uc694 \uc77c\ubc18 \uc758\uc57d\ud488 \uc81c\uc870\uc5c5\uccb4 Alinamin Pharmaceutical\uc758 3500\uc5b5\uc5d4(\uc57d 3\uc870813\uc5b5\uc6d0) \uaddc\ubaa8 \uc778\uc218\uc5d0 \uc790\ubb38\uc744 \uc81c\uacf5\ud558\uace0 \uc788\ub2e4.<\/p>\n<p>\uc774\ubc88 \uc778\uc218 \uac70\ub798\uc5d0\uc11c\ub294 \uc544\uc2dc\uc544 \uae30\ubc18 \uc0ac\ubaa8\ud380\ub4dc\uc778 MBK \ud30c\ud2b8\ub108\uc2a4\uac00 \ubbf8\uad6d\uc758 Blackstone Group\uc73c\ub85c\ubd80\ud130 Alinamin Pharmaceutical\uc744 \uc778\uc218\ud558\uba70, Blackstone Group\uc740 \ub9e4\uac01 \ud6c4 \uc18c\uc218 \uc9c0\ubd84\uc744 \uc720\uc9c0\ud558\uac8c \ub41c\ub2e4.<\/p>\n<p>Simpson Thacher &amp; Bartlett\ub294 \uc774\ubc88 \uac70\ub798\uc5d0\uc11c Blackstone\uc744 \ub300\ub9ac\ud558\uace0 \uc788\ub2e4. \uc774 \ub85c\ud38c\uc740 2021\ub144 Takeda Pharmaceutical\ub85c\ubd80\ud130 Alinamin\uc744 \ucc98\uc74c \uc778\uc218\ud560 \ub54c\ubd80\ud130 Blackstone\uacfc \uc624\ub79c \uad00\uacc4\ub97c \uc720\uc9c0\ud574 \uc654\ub2e4.<\/p>\n<p>M&amp;A \uc804\ubb38\uac00\uc778 Anthony KING, Sonya HO, Paul KIM \ubc0f Tiffany SHIH \ubcc0\ud638\uc0ac\uac00 \ud300\uc744 \uc774\ub04c\uace0 \uc788\ub2e4. \ubc18\ub3c5\uc810 \ubb38\uc81c\uc5d0 \ub300\ud55c \uc8fc\uc694 \uae30\uc5ec\uc790\ub294 \u00c9tienne RENAUDEAU, Sarah CHAUDHURI \ubc0f Luke COWDELL \ubcc0\ud638\uc0ac\ub2e4. \uc740\ud589 \ubc0f \uc2e0\uc6a9 \ubd84\uc57c\uc5d0\uc120 Makiko HARUNARI \ubc0f Chenyu CUI \ubcc0\ud638\uc0ac\uac00 \ub2f4\ub2f9\ud558\uace0 \uc788\uace0 \uc138\uae08 \ubb38\uc81c\ub294 Meredith JONES \ubc0f Paul JANSCH \ubcc0\ud638\uc0ac\uac00 \uc790\ubb38\ud558\uace0 \uc788\ub2e4. IP \uad00\ub828 \uc0ac\ud56d\uc740 Ron BEN-YEHUDA \ubcc0\ud638\uc0ac\uac00 \ucc98\ub9ac\ud558\uace0 \uc788\uc73c\uba70, Steven KLAR \ubc0f Richard ZHANG \ubcc0\ud638\uc0ac\ub294 \ud380\ub4dc \uc804\ubb38 \uc9c0\uc2dd\uc744 \uc81c\uacf5\ud558\uace0 \uc788\ub2e4. Gregory GROGAN \ubc0f Pasco STRUHS \ubcc0\ud638\uc0ac\ub294 \uace0\uc6a9 \ubc0f \ubcf5\ub9ac\ud6c4\uc0dd \ubb38\uc81c\ub97c \uad00\ub9ac\ud558\uace0 \uc788\ub2e4.<\/p>\n<p>Nishimura &amp; Asahi\ub294 MBK Partners\ub97c \ub300\ub9ac\ud558\uace0 \uc788\ub2e4. \uc774 \ub85c\ud38c\uc758 \ud300\uc740 M&amp;A \ubc0f \uae30\uc5c5 \ud30c\ud2b8\ub108\uc778 Hiroshi UCHIMA, Junya KOKAJI \ubc0f Hudson HAMILTON \ubcc0\ud638\uc0ac, \uae08\uc735 \ud30c\ud2b8\ub108\uc778 Toshiyuki NONAKA \ubcc0\ud638\uc0ac, \uc0dd\uba85 \uacfc\ud559 \uaddc\uc81c \ubc0f \uc900\uc218 \ud30c\ud2b8\ub108\uc778 Alisa INUZUKA \ubcc0\ud638\uc0ac \ub4f1\uc774 \uc774\ub04c\uace0 \uc788\ub2e4.<\/p>\n<p>Nishimura &amp; Asahi\ub294 \uc55e\uc11c 2019\ub144 Takeda Pharmaceutical\uc758 Shire \uc778\uc218\uc5d0 \uc790\ubb38\uc744 \uc81c\uacf5\ud55c \ubc14 \uc788\ub2e4.<\/p>\n<p>Alinamin Pharmaceutical\uc740 \uc911\uad6d, \ud55c\uad6d \ubc0f \ud0dc\uad6d\uc5d0\uc11c \uc2dc\uc7a5 \uc785\uc9c0\ub97c \ud655\ub300\ud560 \uacc4\ud68d\uc774\ub2e4.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simpson Thacher &amp; Bartlett\uacfc Nishimura &amp; Asahi\uac00 \uc77c\ubcf8\uc758 \uc8fc\uc694 \uc77c\ubc18 \uc758\uc57d\ud488 \uc81c\uc870\uc5c5\uccb4 Alinamin Pharmaceutical\uc758 3500\uc5b5\uc5d4(\uc57d 3\uc870813\uc5b5\uc6d0) \uaddc\ubaa8 \uc778\uc218\uc5d0 \uc790\ubb38\uc744 \uc81c\uacf5\ud558\uace0 \uc788\ub2e4. \uc774\ubc88 \uc778\uc218 \uac70\ub798\uc5d0\uc11c\ub294 \uc544\uc2dc\uc544 \uae30\ubc18 \uc0ac\ubaa8\ud380\ub4dc\uc778 MBK \ud30c\ud2b8\ub108\uc2a4\uac00 \ubbf8\uad6d\uc758 Blackstone Group\uc73c\ub85c\ubd80\ud130 Alinamin Pharmaceutical\uc744 \uc778\uc218\ud558\uba70, Blackstone Group\uc740 \ub9e4\uac01 \ud6c4 \uc18c\uc218 \uc9c0\ubd84\uc744 \uc720\uc9c0\ud558\uac8c \ub41c\ub2e4. Simpson Thacher &amp; Bartlett\ub294 \uc774\ubc88 \uac70\ub798\uc5d0\uc11c Blackstone\uc744 \ub300\ub9ac\ud558\uace0 \uc788\ub2e4. \uc774 \ub85c\ud38c\uc740 2021\ub144<\/p>\n","protected":false},"author":13501,"featured_media":503518,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"sfsi_plus_gutenberg_text_before_share":"","sfsi_plus_gutenberg_show_text_before_share":"","sfsi_plus_gutenberg_icon_type":"","sfsi_plus_gutenberg_icon_alignemt":"","sfsi_plus_gutenburg_max_per_row":"","meta-author":""},"categories":[8398,8532],"tags":[148177,148180,148175,148183,148178,148174,148182,148176,148181,148179],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.7 (Yoast SEO v17.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<meta name=\"description\" content=\"Simpson Thacher &amp; Bartlett\uacfc Nishimura &amp; Asahi\uac00 \uc77c\ubcf8\uc758 \uc8fc\uc694 \uc77c\ubc18 \uc758\uc57d\ud488 \uc81c\uc870\uc5c5\uccb4 Alinamin Pharmaceutical\uc758 3500\uc5b5\uc5d4(\uc57d 3\uc870813\uc5b5\uc6d0) \uaddc\ubaa8 \uc778\uc218\uc5d0 \uc790\ubb38\uc744 \uc81c\uacf5\ud558\uace0 \uc788\ub2e4.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/\" \/>\n<meta property=\"og:locale\" content=\"ko_KR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simpson \ubc0f Nishimura, 3\uc870\uc6d0\ub300 \uaddc\ubaa8 \uc77c\ubcf8 \uc81c\uc57d\uc0ac \uc778\uc218\uc5d0 \uc790\ubb38 \uc81c\uacf5\" \/>\n<meta property=\"og:description\" content=\"Simpson Thacher &amp; Bartlett\uacfc Nishimura &amp; Asahi\uac00 \uc77c\ubcf8\uc758 \uc8fc\uc694 \uc77c\ubc18 \uc758\uc57d\ud488 \uc81c\uc870\uc5c5\uccb4 Alinamin Pharmaceutical\uc758 3500\uc5b5\uc5d4(\uc57d 3\uc870813\uc5b5\uc6d0) \uaddc\ubaa8 \uc778\uc218\uc5d0 \uc790\ubb38\uc744 \uc81c\uacf5\ud558\uace0 \uc788\ub2e4.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/\" \/>\n<meta property=\"og:site_name\" content=\"Law.asia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AsiaBusinessLaw\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-19T03:19:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/law.asia\/wp-content\/uploads\/2024\/07\/Simpson-Nishimura-act-on-USD2.1bn-Japan-pharma-buyout.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ablj_insights\" \/>\n<meta name=\"twitter:site\" content=\"@ablj_insights\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Website team 05\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/law.asia\/ko\/#organization\",\"name\":\"Law.asia\",\"url\":\"https:\/\/law.asia\/ko\/\",\"sameAs\":[\"https:\/\/www.facebook.com\/AsiaBusinessLaw\/\",\"https:\/\/www.instagram.com\/law.asia_\/?hl=en\",\"https:\/\/www.linkedin.com\/company\/asiabusinesslawjournal\/\",\"https:\/\/www.youtube.com\/@Law.asiaLimited\",\"https:\/\/twitter.com\/ablj_insights\"],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/law.asia\/ko\/#logo\",\"inLanguage\":\"ko-KR\",\"url\":\"https:\/\/law.asia\/wp-content\/uploads\/2020\/10\/LAWDOTASIA-LOGO-152.png\",\"contentUrl\":\"https:\/\/law.asia\/wp-content\/uploads\/2020\/10\/LAWDOTASIA-LOGO-152.png\",\"width\":152,\"height\":152,\"caption\":\"Law.asia\"},\"image\":{\"@id\":\"https:\/\/law.asia\/ko\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/law.asia\/ko\/#website\",\"url\":\"https:\/\/law.asia\/ko\/\",\"name\":\"Law.asia\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/law.asia\/ko\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/law.asia\/ko\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ko-KR\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#primaryimage\",\"inLanguage\":\"ko-KR\",\"url\":\"https:\/\/law.asia\/wp-content\/uploads\/2024\/07\/Simpson-Nishimura-act-on-USD2.1bn-Japan-pharma-buyout.jpg\",\"contentUrl\":\"https:\/\/law.asia\/wp-content\/uploads\/2024\/07\/Simpson-Nishimura-act-on-USD2.1bn-Japan-pharma-buyout.jpg\",\"width\":900,\"height\":600,\"caption\":\"Japan pharma buyout\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#webpage\",\"url\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/\",\"name\":\"\\uc2ec\\uc2a8, \\ub2c8\\uc2dc\\ubb34\\ub77c 21\\uc5b5\\ub2ec\\ub7ec \\uc77c\\ubcf8 \\uc81c\\uc57d\\ud68c\\uc0ac \\uc778\\uc218\\uc5d0 \\ud569\\uc758\\uff5c\\ud55c\\uad6d\\uc5b4 \\ubc84\\uc804\\uff5cLaw.asia\",\"isPartOf\":{\"@id\":\"https:\/\/law.asia\/ko\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#primaryimage\"},\"datePublished\":\"2024-07-19T03:19:23+00:00\",\"dateModified\":\"2024-07-19T03:19:23+00:00\",\"description\":\"Simpson Thacher & Bartlett\\uacfc Nishimura & Asahi\\uac00 \\uc77c\\ubcf8\\uc758 \\uc8fc\\uc694 \\uc77c\\ubc18 \\uc758\\uc57d\\ud488 \\uc81c\\uc870\\uc5c5\\uccb4 Alinamin Pharmaceutical\\uc758 3500\\uc5b5\\uc5d4(\\uc57d 3\\uc870813\\uc5b5\\uc6d0) \\uaddc\\ubaa8 \\uc778\\uc218\\uc5d0 \\uc790\\ubb38\\uc744 \\uc81c\\uacf5\\ud558\\uace0 \\uc788\\ub2e4.\",\"breadcrumb\":{\"@id\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#breadcrumb\"},\"inLanguage\":\"ko-KR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\"}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#webpage\"},\"author\":{\"@id\":\"https:\/\/law.asia\/ko\/#\/schema\/person\/1eb0eca4569d71fa927502833bd61d4b\"},\"headline\":\"Simpson \\ubc0f Nishimura, 3\\uc870\\uc6d0\\ub300 \\uaddc\\ubaa8 \\uc77c\\ubcf8 \\uc81c\\uc57d\\uc0ac \\uc778\\uc218\\uc5d0 \\uc790\\ubb38 \\uc81c\\uacf5\",\"datePublished\":\"2024-07-19T03:19:23+00:00\",\"dateModified\":\"2024-07-19T03:19:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#webpage\"},\"wordCount\":89,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/law.asia\/ko\/#organization\"},\"image\":{\"@id\":\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/law.asia\/wp-content\/uploads\/2024\/07\/Simpson-Nishimura-act-on-USD2.1bn-Japan-pharma-buyout.jpg\",\"keywords\":[\"MBK \\ud30c\\ud2b8\\ub108\\uc2a4\",\"\\uad6d\\uacbd\\uc744 \\ub118\\ub294 \\uc778\\uc218\",\"\\ub2c8\\uc2dc\\ubb34\\ub77c &amp; \\uc544\\uc0ac\\ud788\",\"\\ubc95\\ub960 \\uc790\\ubb38\",\"\\ube14\\ub799\\uc2a4\\ud1a4 \\uadf8\\ub8f9\",\"\\uc2ec\\uc2a8 \\ud0c0\\ucc98 &amp; \\ubc14\\ud2c0\\ub81b\",\"\\uc544\\uc2dc\\uc544 \\ud0dc\\ud3c9\\uc591 \\ud655\\uc7a5\",\"\\uc54c\\ub9ac\\ub098\\ubbfc \\uc81c\\uc57d\",\"\\uc81c\\uc57d \\uc0b0\\uc5c5\",\"\\ud569\\ubcd1 \\ubc0f \\uc778\\uc218\"],\"articleSection\":[\"Asia Business Law Journal\",\"\\ub274\\uc2a4\"],\"inLanguage\":\"ko-KR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\/\/law.asia\/#organization\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/law.asia\/ko\/#\/schema\/person\/1eb0eca4569d71fa927502833bd61d4b\",\"name\":\"Website team 05\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/law.asia\/ko\/#personlogo\",\"inLanguage\":\"ko-KR\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9aabbf305ce0ba4ee191f1c8271609b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9aabbf305ce0ba4ee191f1c8271609b1?s=96&d=mm&r=g\",\"caption\":\"Website team 05\"},\"url\":\"https:\/\/law.asia\/ko\/author\/johnmanson\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"description":"Simpson Thacher & Bartlett\uacfc Nishimura & Asahi\uac00 \uc77c\ubcf8\uc758 \uc8fc\uc694 \uc77c\ubc18 \uc758\uc57d\ud488 \uc81c\uc870\uc5c5\uccb4 Alinamin Pharmaceutical\uc758 3500\uc5b5\uc5d4(\uc57d 3\uc870813\uc5b5\uc6d0) \uaddc\ubaa8 \uc778\uc218\uc5d0 \uc790\ubb38\uc744 \uc81c\uacf5\ud558\uace0 \uc788\ub2e4.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/","og_locale":"ko_KR","og_type":"article","og_title":"Simpson \ubc0f Nishimura, 3\uc870\uc6d0\ub300 \uaddc\ubaa8 \uc77c\ubcf8 \uc81c\uc57d\uc0ac \uc778\uc218\uc5d0 \uc790\ubb38 \uc81c\uacf5","og_description":"Simpson Thacher & Bartlett\uacfc Nishimura & Asahi\uac00 \uc77c\ubcf8\uc758 \uc8fc\uc694 \uc77c\ubc18 \uc758\uc57d\ud488 \uc81c\uc870\uc5c5\uccb4 Alinamin Pharmaceutical\uc758 3500\uc5b5\uc5d4(\uc57d 3\uc870813\uc5b5\uc6d0) \uaddc\ubaa8 \uc778\uc218\uc5d0 \uc790\ubb38\uc744 \uc81c\uacf5\ud558\uace0 \uc788\ub2e4.","og_url":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/","og_site_name":"Law.asia","article_publisher":"https:\/\/www.facebook.com\/AsiaBusinessLaw\/","article_published_time":"2024-07-19T03:19:23+00:00","og_image":[{"width":900,"height":600,"url":"https:\/\/law.asia\/wp-content\/uploads\/2024\/07\/Simpson-Nishimura-act-on-USD2.1bn-Japan-pharma-buyout.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_creator":"@ablj_insights","twitter_site":"@ablj_insights","twitter_misc":{"Written by":"Website team 05"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/law.asia\/ko\/#organization","name":"Law.asia","url":"https:\/\/law.asia\/ko\/","sameAs":["https:\/\/www.facebook.com\/AsiaBusinessLaw\/","https:\/\/www.instagram.com\/law.asia_\/?hl=en","https:\/\/www.linkedin.com\/company\/asiabusinesslawjournal\/","https:\/\/www.youtube.com\/@Law.asiaLimited","https:\/\/twitter.com\/ablj_insights"],"logo":{"@type":"ImageObject","@id":"https:\/\/law.asia\/ko\/#logo","inLanguage":"ko-KR","url":"https:\/\/law.asia\/wp-content\/uploads\/2020\/10\/LAWDOTASIA-LOGO-152.png","contentUrl":"https:\/\/law.asia\/wp-content\/uploads\/2020\/10\/LAWDOTASIA-LOGO-152.png","width":152,"height":152,"caption":"Law.asia"},"image":{"@id":"https:\/\/law.asia\/ko\/#logo"}},{"@type":"WebSite","@id":"https:\/\/law.asia\/ko\/#website","url":"https:\/\/law.asia\/ko\/","name":"Law.asia","description":"","publisher":{"@id":"https:\/\/law.asia\/ko\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/law.asia\/ko\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ko-KR"},{"@type":"ImageObject","@id":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#primaryimage","inLanguage":"ko-KR","url":"https:\/\/law.asia\/wp-content\/uploads\/2024\/07\/Simpson-Nishimura-act-on-USD2.1bn-Japan-pharma-buyout.jpg","contentUrl":"https:\/\/law.asia\/wp-content\/uploads\/2024\/07\/Simpson-Nishimura-act-on-USD2.1bn-Japan-pharma-buyout.jpg","width":900,"height":600,"caption":"Japan pharma buyout"},{"@type":"WebPage","@id":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#webpage","url":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/","name":"\uc2ec\uc2a8, \ub2c8\uc2dc\ubb34\ub77c 21\uc5b5\ub2ec\ub7ec \uc77c\ubcf8 \uc81c\uc57d\ud68c\uc0ac \uc778\uc218\uc5d0 \ud569\uc758\uff5c\ud55c\uad6d\uc5b4 \ubc84\uc804\uff5cLaw.asia","isPartOf":{"@id":"https:\/\/law.asia\/ko\/#website"},"primaryImageOfPage":{"@id":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#primaryimage"},"datePublished":"2024-07-19T03:19:23+00:00","dateModified":"2024-07-19T03:19:23+00:00","description":"Simpson Thacher & Bartlett\uacfc Nishimura & Asahi\uac00 \uc77c\ubcf8\uc758 \uc8fc\uc694 \uc77c\ubc18 \uc758\uc57d\ud488 \uc81c\uc870\uc5c5\uccb4 Alinamin Pharmaceutical\uc758 3500\uc5b5\uc5d4(\uc57d 3\uc870813\uc5b5\uc6d0) \uaddc\ubaa8 \uc778\uc218\uc5d0 \uc790\ubb38\uc744 \uc81c\uacf5\ud558\uace0 \uc788\ub2e4.","breadcrumb":{"@id":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#breadcrumb"},"inLanguage":"ko-KR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home"}]},{"@type":"NewsArticle","@id":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#article","isPartOf":{"@id":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#webpage"},"author":{"@id":"https:\/\/law.asia\/ko\/#\/schema\/person\/1eb0eca4569d71fa927502833bd61d4b"},"headline":"Simpson \ubc0f Nishimura, 3\uc870\uc6d0\ub300 \uaddc\ubaa8 \uc77c\ubcf8 \uc81c\uc57d\uc0ac \uc778\uc218\uc5d0 \uc790\ubb38 \uc81c\uacf5","datePublished":"2024-07-19T03:19:23+00:00","dateModified":"2024-07-19T03:19:23+00:00","mainEntityOfPage":{"@id":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#webpage"},"wordCount":89,"commentCount":0,"publisher":{"@id":"https:\/\/law.asia\/ko\/#organization"},"image":{"@id":"https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#primaryimage"},"thumbnailUrl":"https:\/\/law.asia\/wp-content\/uploads\/2024\/07\/Simpson-Nishimura-act-on-USD2.1bn-Japan-pharma-buyout.jpg","keywords":["MBK \ud30c\ud2b8\ub108\uc2a4","\uad6d\uacbd\uc744 \ub118\ub294 \uc778\uc218","\ub2c8\uc2dc\ubb34\ub77c &amp; \uc544\uc0ac\ud788","\ubc95\ub960 \uc790\ubb38","\ube14\ub799\uc2a4\ud1a4 \uadf8\ub8f9","\uc2ec\uc2a8 \ud0c0\ucc98 &amp; \ubc14\ud2c0\ub81b","\uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \ud655\uc7a5","\uc54c\ub9ac\ub098\ubbfc \uc81c\uc57d","\uc81c\uc57d \uc0b0\uc5c5","\ud569\ubcd1 \ubc0f \uc778\uc218"],"articleSection":["Asia Business Law Journal","\ub274\uc2a4"],"inLanguage":"ko-KR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/law.asia\/ko\/simpson-nishimura-japan-pharma-buyout\/#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/law.asia\/#organization"}},{"@type":"Person","@id":"https:\/\/law.asia\/ko\/#\/schema\/person\/1eb0eca4569d71fa927502833bd61d4b","name":"Website team 05","image":{"@type":"ImageObject","@id":"https:\/\/law.asia\/ko\/#personlogo","inLanguage":"ko-KR","url":"https:\/\/secure.gravatar.com\/avatar\/9aabbf305ce0ba4ee191f1c8271609b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9aabbf305ce0ba4ee191f1c8271609b1?s=96&d=mm&r=g","caption":"Website team 05"},"url":"https:\/\/law.asia\/ko\/author\/johnmanson\/"}]}},"_links":{"self":[{"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/posts\/503559"}],"collection":[{"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/users\/13501"}],"replies":[{"embeddable":true,"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/comments?post=503559"}],"version-history":[{"count":1,"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/posts\/503559\/revisions"}],"predecessor-version":[{"id":503571,"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/posts\/503559\/revisions\/503571"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/media\/503518"}],"wp:attachment":[{"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/media?parent=503559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/categories?post=503559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/law.asia\/ko\/wp-json\/wp\/v2\/tags?post=503559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}